Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/InspireMD Inc./ 424B5

SEC Filing · 424B5

InspireMD Inc.

NSPRNASDAQEQUITYCurrent

SEC Filing

Filed Nov 12, 2026Accepted Nov 12, 2026, 5:24 PM ESTCIK 1433607Accession 0001493152-26-051492
View company →Permanent SEC source ↗
Share

Company context

InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Current securities

NSPRNASDAQ · EQUITY · Current
Historical securities (4)
NSPRWNASDAQ · WARRANT · Historical · closed Jul 7, 2021NSPR.WSAMEX · WARRANT · Historical · closed Jun 7, 2021NSPR.WS.BNYSE_AMERICAN · WARRANT · Historical · closed Jun 7, 2021NSPRZNASDAQ · WARRANT · Historical · closed Mar 15, 2022

Recent company filings

  1. Results of Operations and Financial Condition · Other EventsNov 12, 2026
  2. Regulation FD Disclosure · Other EventsNov 12, 2026
  3. 4 filingSep 23, 2026
  4. 4 filingSep 23, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureSep 21, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.